This mechanism was particularly evident in patients with BRCA-mutated ovarian cancer, where deficient DNA repair capacity (due to BRCA mutation) led to enhanced effects of PARP inhibition and subsequently amplified the immune-stimulating action of the cGAS-STING pathway. Here, CGAS is linked to ovarian cancer.